[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eugene F Yen, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100365871","phase-2-efficacy-and-safety-of-oral-rifaximin-in-patients-with-active-microscopic-colitis-100365871",false,"NCT04043897","Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis","Inclusion Criteria:\n\n* Collagenous colitis (CC) or lymphocytic colitis (LC) diagnosed on colon biopsies reviewed by 2 separate pathologists\n* CC will be defined histologically to be the following: thickness of the collagenous subepithelial table \\>10 micrometer using an ocular micrometer, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, lack of crypt architectural distortion, and regenerative-appearing changes in the surface and\u002For crypt epithelium\n* LC will be defined histologically to be the following: intraepithelial lymphocytes \\>20 per 100 epithelial cells in the subjective area of highest lymphocyte density, inflammation in the lamina propria consisting of mainly lymphocytes and plasma cells, and regenerative-appearing changes in the surface and\u002For crypt epithelium\n* Subjects in active flare, defined as \\>3 watery\u002Floose stools per day on \\>4 \u002F 7 days over \\>4 weeks in the past 3 months.\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.",[25],"Microscopic Colitis",[25],"RECRUITING","2021-04-14",{"date":30,"type":31},"2021-04-15","ACTUAL",{"date":33,"type":31},"2018-06-29",{"date":35,"type":19},"2021-12",{"name":37,"class":38},"Eugene F Yen, MD","OTHER",""]